

Role of the pectoralis major myofascial flap in preventing pharyngocutaneous fistula following salvage laryngectomy

S SHARMA¹, D A CHAUKAR¹, S G LASKAR², N KAPRE¹, A DESHMUKH¹, P PAI¹,
P CHATURVEDI¹, A D'CRUZ¹

Departments of ¹Head Neck Services and ²Radiation Oncology, Tata Memorial Hospital, Mumbai, India

Abstract

Objective: This study aimed to assess the utility of onlay pectoralis major myofascial flap in preventing pharyngocutaneous fistula following salvage total laryngectomy.

Methods: A retrospective analysis was performed of 172 patients who underwent salvage laryngectomy for recurrent carcinoma of the larynx or hypopharynx between 1999 and 2014. One hundred and ten patients underwent primary closure and 62 patients had pectoralis major myofascial flap onlay.

Results: The overall pharyngocutaneous fistula rate was 43 per cent, and was similar in both groups (primary closure group, 43.6 per cent; onlay flap group, 41.9 per cent; $p = 0.8$). Fistulae in the onlay flap group healed faster: the median and mean fistula duration were 37 and 55 days, respectively, in the primary closure group and 20 and 25 days, respectively, in the onlay flap group ($p = 0.008$).

Conclusion: Use of an onlay pectoralis major myofascial flap did not decrease the pharyngocutaneous fistula rate, although fistula duration was shortened. A well-designed randomised-controlled trial is needed to establish parameters for its routine use in clinical practice.

Key words: Fistula; Laryngectomy; Surgical Flaps

Introduction

There has been a paradigm shift in the management of locoregionally advanced laryngopharyngeal cancers towards non-surgical treatment over the last two decades based on the findings of two pivotal trials.^{1,2} This has led to an increased number of salvage laryngectomies. It is well established that post-operative complications are higher in post-radiotherapy or post-chemoradiotherapy settings.^{3,4} The incidence of pharyngocutaneous fistulae could be as high as 14–57 per cent following salvage laryngectomy, as opposed to 9–25 per cent in the primary setting.^{5–10} An intuitively attractive option is to introduce non-irradiated, vascularised tissue into the irradiated bed. Of the various methods described, the pectoralis major myofascial flap is the most common and widely accepted.¹¹ Opinions in the literature are divided whether it has a definite role in salvage settings. This study aimed to review fistula rates in patients undergoing salvage laryngectomy and to assess the impact of onlay vascularised flap use in reducing its frequency and severity.

Materials and methods

A retrospective analysis of patients who underwent salvage total laryngectomy between January 1999 and December 2014 was performed. Patients for whom primary pharyngeal closure was not possible and those who required pharyngeal mucosa augmentation were excluded. The study comprised 172 patients who underwent primary pharyngeal closure in two groups: a primary closure group (110 patients) and an onlay pectoralis major muscle flap group (onlay flap group; 62 patients). Thirteen patients requiring spiral pectoralis major myocutaneous flaps were included in the onlay flap group.

Patient data were extracted from the Hospital Information System and electronic medical records, a comprehensive synoptic electronic database maintained by clinicians in the multidisciplinary treatment team and updated at each follow up, thus ensuring effective, correct data capture. Demographic, clinical, biochemical, surgical and histological data, and post-operative complication details were obtained. The time to

development and duration of fistula, length of hospital stay, and re-hospitalisation rates were recorded.

Surgical technique

Standard salvage total laryngectomy with primary pharyngeal closure was performed as previously described.¹² The decision to use a pectoralis major myofascial flap was made by the operating surgeon. For this procedure, the pectoralis major muscle was harvested without a skin paddle, and fascia over the muscle was kept intact. The flap was delivered into the neck through a tunnel below the skin and used to buttress the suture line. The flap was anchored to the base tongue superiorly and to the pre-vertebral fascia medial to carotid artery on both sides.

A total of 156 patients had a Provox voice prosthesis (Atos Medical, Horby, Malmö, Sweden) inserted. The procedure was not carried out in 16 patients for various reasons such as financial issues or poor local tissue condition.

Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics software version 20.0 (Armonk, New York, USA). Chi-squared and Fischer's exact test were used in univariable analyses. Cox regression analysis using the binary logistic forward regression method was used for multivariable analyses. Unpaired Student's *t*-tests were used to compare the means of fistula duration between groups.

Results

The median patient age was 58 years (range 30–89 years) and most patients (97.1 per cent) were men. In all, 127 patients (73.8 per cent) had glottic cancers, 17 (9.9 per cent) had supraglottic cancers and 28 (16.3 per cent) had hypopharyngeal cancers. Data on pre-treatment staging were not available for 12 patients because they received primary treatment elsewhere. Of the remaining 160 patients, 99 (61.8 per cent) had tumour–node–metastasis stage T_{1–2} tumours, 58 (36.3 per cent) had T₃ tumours and 3 (1.9 per cent) had stage T₄ tumours. A total of 112 patients (65.1 per cent) had received prior radiotherapy and 60 (34.9 per cent) had received chemoradiotherapy. The suture line was reinforced in 62 patients. Compared with the primary closure group, a higher proportion of patients in the onlay flap group had hypopharynx involvement (22.7 per cent vs 37.1 per cent), a higher prior tracheostomy rate (22.7 per cent vs 41.9 per cent), more pathologically staged T₄ disease (39.5 per cent vs 59.7 per cent), more patients with pre-operative haemoglobin levels of less than 12.5 g/dl (34.9 per cent vs 68.6 per cent), more positive tumour margins (3.7 per cent vs 12.9 per cent) and more patients who underwent extended neck dissection (8.3 per cent vs 19.4 per cent). Fewer patients in the onlay flap group had a tracheoesophageal puncture (94.5 per cent vs

83.9 per cent). All other variables were equally distributed between groups (Table I).

Pharyngocutaneous fistulae

A total of 74 patients developed pharyngocutaneous fistulae, corresponding to an overall fistula rate of 43 per cent: 48 patients (43.6 per cent) in the primary closure group and 26 patients (41.9 per cent) in the onlay flap group. The difference was not statistically significant ($p = 0.8$). Sixty-five fistulae (87.8 per cent) healed with conservative management. Nine patients (12.2 per cent) required surgical exploration: seven from the primary closure group (6.3 per cent) and two from the onlay flap group (3.2 per cent). Although the primary closure group had a higher incidence of fistulae requiring surgical intervention (6.3 per cent vs 3.2 per cent), the difference was not statistically significant ($p = 0.48$).

The time to fistula manifestation was similar for both study groups. The median and meantime to fistula formation was 15.0 days and 18.8 days, respectively, in the primary closure group, and 15.5 days and 16.9 days, respectively, in the onlay flap group ($p = 0.5$, 95 per cent confidence interval (CI), 4.281 to 8.076).

The median and mean fistula duration were 37 and 55 days, respectively, in the primary closure group and 20 and 25 days, respectively, in the onlay flap group. Thus, fistulae took longer to heal in the primary closure group than in the onlay flap group; this difference was statistically significant ($p = 0.008$, 95 per cent CI, 8.059 to 52.016).

The mean hospital stay was longer for patients with a fistula than those without (18.8 days vs 10.5 days, $p = 0.001$, 95 per cent CI, 5.26 to 11.29). However, the length of hospital stay was similar for both the primary closure and onlay flap groups (19.56 days vs 17.38 days, $p = 0.52$; 95 per cent CI, 8.9 to 4.6). The rates of re-hospitalisation did not differ between groups (37.5 per cent vs 34.6 per cent, $p = 0.8$).

Voice outcome

Data on physician's opinions of voice outcome were retrieved from the hospital electronic medical records. The voice was considered satisfactory in 150 patients (96.2 per cent) over a mean follow-up period of 34 months. Similar voice outcomes were obtained for both the groups.

Discussion

The incidence and severity of pharyngocutaneous fistula are higher in patients who have received prior radiotherapy. Radiotherapy-induced tissue damage in the form of tissue fibrosis and obliterative endarteritis may therefore be an important contributory factor.¹³ Pharyngocutaneous fistula is a common complication of laryngectomy, causing considerable post-operative morbidity. It increases the length of hospital stay, delays oral feeding and may lead to serious vascular complications. In the long term, it may lead to an increased incidence of pharyngeal stenosis that affects

TABLE I
PATIENT DETAILS

Variable	Primary closure group (n (%))	Onlay flap group (n (%))
n	110 (64.3)	62 (35.7)
Age, mean (years)	58.07	58.13
Comorbidity		
– No	81 (73.6)	39 (62.9)
– Yes	29 (26.4)	23 (37.1)
Sex		
– Male	107 (97.3)	60 (96.8)
– Female	3 (2.7)	2 (3.2)
Prior treatment		
– Radiotherapy	75 (68.2)	37 (59.7)
– Chemoradiotherapy	35 (31.8)	25 (40.3)
Site		
– Glottis	83 (75.5)	44 (71)
– Supraglottis	13 (11.8)	4 (6.4)
– Hypopharynx	14 (12.7)	14 (22.6)
Hypopharynx involvement at surgery		
– Yes	25 (22.7)	23 (37.1)
– No	85 (77.3)	39 (62.9)
Prior tracheostomy		
– Yes	25 (22.7)	26 (41.9)
– No	85 (77.3)	36 (58.1)
Pre-operative haemoglobin*		
– <12.5 g/dl	30 (34.9)	35 (68.6)
– >12.5 g/dl	56 (65.1)	16 (31.4)
Post-operative haemoglobin*		
– <12.5 g/dl	66 (77.6)	43 (89.6)
– >12.5 g/dl	19 (22.4)	5 (10.4)
Pre-operative albumin*		
– Less than 3 g/dl	2 (1.9)	4 (6.6)
– More than 3 g/dl	104 (98.1)	56 (93.4)
Pathological node status [†]		
– N ₀	95 (87.2)	50 (80.6)
– N ⁺	14 (12.8)	12 (19.4)
Peri-neural invasion [†]		
– Yes	12 (11)	11 (17.7)
– No	97 (89)	51 (82.3)
Surgical margin [†]		
– Negative or close	105 (96.3)	54 (87.1)
– Positive	4 (3.7)	8 (12.9)
Pathological tumour stage [†]		
– T ₀	2 (1.8)	5 (8.0)
– T ₁	1 (0.9)	0 (0.0)
– T ₂	22 (20.2)	4 (6.5)
– T ₃	41 (37.6)	16 (25.8)
– T ₄	43 (39.5)	37 (59.7)
Neck dissection [†]		
– None	6 (5.5)	10 (16.1)
– Level II–IV	94 (86.2)	40 (64.5)
– level II–V	9 (8.3)	12 (19.4)
Extracapsular spread [†]		
– Negative	100 (91.7)	54 (87.1)
– Positive	9 (8.3)	8 (12.9)
Soft tissue infiltration [†]		
– Yes	46 (42.2)	23 (35.5)
– No	63 (57.8)	40 (64.5)
Thyroid gland involvement [†]		
– Yes	10 (9.2)	7 (11.3)
– No	99 (90.8)	55 (88.7)
Tumour grade [†]		
– Well differentiated	1 (0.9)	0 (0.0)
– Moderately differentiated	58 (52.7)	29 (46.8)
– Poorly differentiated	41 (37.3)	27 (43.5)
– Not available	10 (9.1)	6 (9.7)
Tracheoesophageal puncture		

Continued

– Yes	104 (94.5)	52 (83.9)
– No	6 (5.5)	10 (16.1)

*Data missing for some patients. [†]Data missing for one patient. [‡]No residual tumour in seven patients, tumour grade not mentioned for eight patients and data missing for one patient

swallowing and the voice. Over the years, the focus of research has been to provide a suitable surgical solution to this morbidity. The use of vascularised tissue flaps appears a logical method to reduce fistula rates in post-irradiated patients. Flaps can be either interpositional or onlay (i.e. over the suture line). Interpositional flaps are usually used to augment inadequate pharyngeal mucosa. The use of free flaps (interpositional and onlay) has been shown to decrease the incidence or severity of fistula.^{14–16} Although free flaps provide vascularised tissue, they require surgical expertise, a compatible infrastructure, prolonged surgery, and special monitoring of flap; they also carry a risk of flap failure. The sternocleidomastoid muscle or infrahyoid musculature is within the radiation field, which precludes their use in local flaps.^{17,18}

- **The pectoralis major myofascial flap is commonly used to reduce fistula rates in salvage settings**
- **Evidence for its efficacy comes from retrospective studies**
- **In this study, it did not reduce fistula incidence, promoted faster healing and prevented major complications**
- **Its drawbacks are shoulder dysfunction, an unsightly appearance at the neck and possible long-term complications**

Use of a pectoralis major myofascial flap as an onlay flap over the suture line is the most widely accepted option. Advantages of this technique are the ease of flap harvest and the ability to be performed simultaneously with primary closure of the pharynx, thus reducing the overall surgery time. Initial reports generated great enthusiasm due to the considerable decrease in fistula rates.^{19,20} Patel and Keni reported no fistula formation with the use of a pectoralis major myofascial flap in a series of 10 patients.²⁰ Various studies subsequently reported significant reductions in fistula rates.^{21–26} Righini *et al.* reported a reduction in fistula rates from 50 per cent to 23 per cent with the use of pectoralis myofascial flaps compared with the no flap group, although the difference was not significant.²⁷ A few of the others failed to show a reduction in fistula rates (Table II).^{28,29} The present study, which is one of the largest, also did not show a significant difference in fistula rate between groups (43.6 per cent in the primary closure group vs 41.9 per cent in the onlay flap group). However, more patients in the onlay flap group had known risk factors for fistula formation such as low

TABLE II
ONLAY PMMF AND THEIR OUTCOMES: PUBLISHED STUDIES

Study author	Study type	Non-PMMF group (n)	Onlay PMMF group (n)	PCF rate		Reduction in fistula rate*
				Non-PMMF (%)	PMMF (%)	
Smith <i>et al.</i> ¹⁹	Retrospective	55	40	22.9	1	Yes
Righini <i>et al.</i> ²⁷	Retrospective	34	26	50	23	No
Gil <i>et al.</i> ²⁸	Retrospective	69	11	24	27	No
Patel and Keni ²⁰	Retrospective	7	10	57	0	Yes
Sundaram & Wasserman ³¹	Case series, no control group	–	11	–	0	Yes
Oosthuizen <i>et al.</i> ²¹	Retrospective	2	8	50	25	Yes
Sakai <i>et al.</i> ²²	Retrospective	39	13	30.1	7.7	Yes
Patel <i>et al.</i> ²³	Retrospective	99	40	34	15	Yes
Gendreau-Lefevre <i>et al.</i> ²⁴	Retrospective	115	51	36	14	Yes
Cömert <i>et al.</i> ²⁹	Retrospective	24	21	58.3	42.8	No
Gilbert <i>et al.</i> ²⁵	Retrospective	34	21	45	10	Yes
Rothmeier <i>et al.</i> ²⁶	Retrospective	3	6	33	0	Yes
Current study	Retrospective	110	62	43.6	41.9	No

*Statistically significant. PMMF = pectoralis major myofascial flap; PCF = pharyngocutaneous fistula

pre-operative haemoglobin levels, prior tracheostomy, T₄ tumours, positive tumour margins and hypopharyngeal involvement. Thus, despite including more at-risk patients, the fistula rate was not higher in the onlay flap group than in the control group. This could be considered indirect evidence to support the use of onlay flap in salvage settings. Patients in the onlay flap group healed faster, leading to early fistula closure. Fistula severity was also reduced in the onlay flap group, although the difference was not significant, probably due to a low incidence of major fistula (nine patients). This important endpoint has also been reported in other studies.^{28,29} The increased bulk provided by the onlay flap may theoretically decrease vibrations of pharyngoesophageal segment, thus affecting voice outcomes. In the present study, all but one patient in the onlay flap group had satisfactory voice outcomes. This finding is in accordance with the results of Fung *et al.*, who found that onlay free flaps caused no deterioration in speech.¹⁵ Two published systemic reviews favour the use of onlay flaps in salvage laryngectomy.^{11,30} However, they included only retrospective studies, most had small patient numbers and there was significant asymmetry between studies. One review found onlay flaps to be beneficial following chemoradiotherapy; however, the benefit was smaller in the radiotherapy-alone group, and authors doubted the benefit of flap use in this group.³⁰ Besides, use of the pectoralis major myofascial flap has its own drawbacks: it may lead to the development of long-term disabling complications such as dysphagia, and may be associated with an unsightly appearance at the neck, shoulder dysfunction, local discomfort, additional surgical costs (due to an additional procedure) and problems related to tracheoesophageal puncture such as prosthesis migration and peri-prosthetic granulations.

Limitations of the study

A weakness of this study was its retrospective nature, similar to all other previously published studies on

the subject. There may be selection bias because objective criteria were not used when deciding on the use of the pectoralis major myofascial flap. The decision was made by the operating surgeon, and it is likely that the surgeon used an onlay flap for patients with a severe reaction to radiotherapy, and a primary closure used to close healthier looking tissues. In this study, time to oral feeding and nasogastric tube duration between the onlay flap and primary closure groups could not be compared because these data were not always recorded. This is attributable to the retrospective design of the study. In addition, the impact of pectoralis major myofascial flap on shoulder dysfunction was not analysed, and this should be explored in future studies.

Conclusion

The onlay pectoralis major myofascial flap technique is a useful adjunct for improving the outcome of salvage laryngectomy. It promotes faster healing of fistula and prevents major complications. Although many studies have also found it useful for reducing the fistula rate, it should be remembered that all of the published evidence comes from retrospective studies. Recommendations for its routine use in salvage settings should be based on level I evidence. A well-designed randomised-controlled trial to eliminate confounding factors is therefore required to establish its usefulness in salvage settings.

References

- 1 The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. *N Engl J Med* 1991;**324**:1685–90
- 2 Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W *et al.* Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med* 2003;**349**:2091–8
- 3 Sessler AM, Esclamado RM, Wolf GT. Surgery after organ preservation therapy. Analysis of wound complications. *Arch Otolaryngol Head Neck Surg* 1995;**121**:162–5

- 4 Johansen LV, Overgaard J, Elbrønd O. Pharyngocutaneous fistulae after laryngectomy. Influence of previous radiotherapy and prophylactic metronidazole. *Cancer* 1988;**61**:673–8
- 5 Papazoglou G, Doundoulakis G, Terzakis G, Dokianakis G. Pharyngocutaneous fistula after total laryngectomy: incidence, cause, and treatment. *Ann Otol Rhinol Laryngol* 1994;**103**: 801–5
- 6 Grau C, Johansen LV, Hansen HS, Andersen E, Godballe C, Andersen LJ *et al.* Salvage laryngectomy and pharyngocutaneous fistulae after primary radiotherapy for head and neck cancer: a national survey from DAHANCA. *Head Neck* 2003;**25**:711–16
- 7 Sarkar S, Mehta SA, Tiwari J, Mehta AR, Mehta MS. Complications following surgery for cancer of the larynx and pyriform fossa. *J Surg Oncol* 1990;**43**:245–9
- 8 Aprigliano F. Use of the nasogastric tube after total laryngectomy: is it truly necessary? *Ann Otol Rhinol Laryngol* 1990;**99**:513–14
- 9 Seikaly H, Park P. Gastroesophageal reflux prophylaxis decreases the incidence of pharyngocutaneous fistula after total laryngectomy. *Laryngoscope* 1995;**105**:1220–2
- 10 Qureshi SS, Chaturvedi P, Pai PS, Chaukar DA, Deshpande MS, Pathak KA *et al.* A prospective study of pharyngocutaneous fistulas following total laryngectomy. *J Cancer Res Ther* 2005;**1**: 51–6
- 11 Paleri V, Drinnan M, van den Brekel MW, Hinni ML, Bradley PJ, Wolf GT *et al.* Vascularized tissue to reduce fistula following salvage total laryngectomy: a systematic review. *Laryngoscope* 2014;**124**:1848–53
- 12 Dudley H, Carter D, Russel R, McGregor I, Howard D, eds. *Rob & Smith's Operative Surgery*, 4th edn. London: Butterworth-Heinemann, 1992
- 13 Teknos TN, Myers LL. Surgical reconstruction after chemotherapy or radiation. Problems and solutions. *Hematol Oncol Clin North Am* 1999;**13**:679–87
- 14 Withrow KP, Rosenthal EL, Gourin CG, Peters GE, Magnuson JS, Terris DJ *et al.* Free tissue transfer manage salvage laryngectomy defects after organ preservation failure. *Laryngoscope* 2007;**117**:781–4
- 15 Fung K, Teknos TN, Vandenberg CD, Lyden TH, Bradford CR, Hogikyan ND *et al.* Prevention of wound complications following salvage laryngectomy using free vascularized tissue. *Head Neck* 2007;**29**:425–30
- 16 Higgins KM, Ashford B, Erovic BM, Yoo J, Enepekides DJ. Temporoparietal fascia free flap for pharyngeal coverage after salvage total laryngectomy. *Laryngoscope* 2012;**122**:523–7
- 17 Albirmawy OA. Prevention of post laryngectomy pharyngocutaneous fistula using a sternocleidomastoid muscle collar flap. *J Laryngol Otol* 2007;**121**:253–7
- 18 Kadota H, Fukushima J, Kamizono K, Masuda M, Tanaka S, Yoshida T *et al.* A minimally invasive method to prevent post-laryngectomy major pharyngocutaneous fistula using infrahyoid myofascial flap. *J Plast Reconstr Aesthet Surg* 2013;**66**:906–11
- 19 Smith TJ, Burrage KJ, Ganguly P, Kirby S, Drover C. Prevention of postlaryngectomy pharyngocutaneous fistula: the Memorial University experience. *J Otolaryngol* 2003;**32**: 222–5
- 20 Patel UA, Keni SP. Pectoralis myofascial flap during salvage laryngectomy prevents pharyngocutaneous fistula. *Otolaryngol Head Neck Surg* 2009;**141**:190–5
- 21 Oosthuizen JC, Leonard DS, Kinsella JB. The role of pectoralis major myofascial flap in salvage laryngectomy: a single surgeon experience. *Acta Otolaryngol* 2012;**132**:1002–5
- 22 Sakai A, Okami K, Sugimoto R, Ebisumoto K, Yamamoto H, Maki D *et al.* Prevention of wound complications in salvage pharyngolaryngectomy by the use of well-vascularized flaps. *Acta Otolaryngol* 2012;**132**:778–82
- 23 Patel UA, Moore BA, Wax M, Rosenthal E, Sweeny L, Militsakh ON *et al.* Impact of pharyngeal closure technique on fistula after salvage laryngectomy. *JAMA Otolaryngol Head Neck Surg* 2013;**139**:1156–62
- 24 Gendreau-Lefèvre AK, Audet N, Maltais S, Thuot F. Prophylactic pectoralis major muscle flap in prevention of pharyngocutaneous fistula in total laryngectomy after radiotherapy. *Head Neck* 2015;**37**:1233–8
- 25 Gilbert MR, Sturm JJ, Gooding WE, Johnson JT, Kim S. Pectoralis major myofascial onlay and myocutaneous flaps and pharyngocutaneous fistula in salvage laryngectomy. *Laryngoscope* 2014;**124**: 2680–6
- 26 Rothmeier N, Bergmann C, Mattheis S, Weller P, Lang S. The primary use of pectoralis myofascial flap in salvage laryngectomy. *Laryngorhinootologie* 2015;**94**:232–8
- 27 Righini C, Lequeux T, Cuisnier O, Morel N, Rey E. The pectoralis myofascial flap in pharyngolaryngeal surgery after radiotherapy. *Eur Arch Otorhinolaryngol* 2005;**262**:357–61
- 28 Gil Z, Gupta A, Kummer B, Cordeiro PG, Kraus DH, Shah JP *et al.* The role of pectoralis major muscle flap in salvage total laryngectomy. *Arch Otolaryngol Head Neck Surg* 2009;**135**:1019–23
- 29 Cömert E, Tunçel Ü, Torun MT, Kiliç C, Cengiz AB, Sencan Z *et al.* Pectoralis major myofascial flap in salvage laryngectomy. *J Laryngol Otol* 2014;**128**:714–19
- 30 Sayles M, Grant DG. Preventing pharyngocutaneous fistula in total laryngectomy: a systematic review and meta-analysis. *Laryngoscope* 2014;**124**:1150–63
- 31 Sundaram K, Wasserman JM. Prevention of unplanned pharyngocutaneous fistula in salvage laryngectomy. *Otolaryngol Head Neck Surg* 2009;**141**:645–7

Address for correspondence:

Dr D Chaukar,
1226 Homi Bhabha Block,
Dr E Borges Marg,
Tata Memorial Hospital,
Parel,
Mumbai 400012,
India

Fax: +91 24146937
E-mail: dchaukar@gmail.com

Dr D Chaukar takes responsibility for the integrity of the content of the paper
Competing interests: None declared
